Niagen Bioscience, Inc. filed a Form 8-K on November 4, 2026, disclosing its earnings results for the quarter ended September 30, 2026, and releasing a corporate presentation under Regulation FD.

Key Highlights

  • Earnings announcement: Niagen Bioscience issued a press release on November 4, 2026, announcing earnings for the quarter ended September 30, 2026.
  • Corporate presentation: The company released a corporate presentation on November 4, 2026, made available on its website under Regulation FD.
  • Exhibits filed: The filing attaches two exhibits: Exhibit 99.1 (press release dated November 4, 2026) and Exhibit 99.2 (earnings presentation).
  • Furnished, not filed: According to the filing, the information in Items 2.02 and 7.01 and their exhibits "shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."
  • Signing officer: The report was signed by Ozan Pamir, Chief Financial Officer, identified as the principal financial officer.
  • Exchange listing: The company's Common Stock, par value $0.001 per share, trades on NASDAQ:NAGE on the Nasdaq Capital Market.

Niagen Bioscience Discloses Q3 2026 Results and Corporate Presentation

Niagen Bioscience, Inc., a Delaware-incorporated company headquartered at 10900 Wilshire Blvd., Suite 600, Los Angeles, California 90024, filed a current report on November 4, 2026, covering two items: results of operations and a Regulation FD disclosure. The filing was submitted under Items 2.02 and 7.01 of the reporting requirements, according to the document.

Under Item 2.02, the company disclosed that it issued a press release on November 4, 2026, announcing its earnings for the fiscal quarter ended September 30, 2026. The press release itself is attached as Exhibit 99.1 but its financial details are not reproduced in the body of the 8-K form. The filing states that this information and the accompanying exhibit are "being furnished and shall not be deemed to be 'filed'" under Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings unless expressly stated.

Under Item 7.01, the company disclosed that it released a corporate presentation on the same date, also made available on its website. That presentation is attached as Exhibit 99.2. The same furnishing language applies to this item, limiting its liability under the Exchange Act. The report was signed by Ozan Pamir, identified as Chief Financial Officer and principal financial officer, on behalf of Niagen Bioscience, Inc.

What Was Disclosed

Niagen Bioscience, Inc. filed an 8-K on November 4, 2026, furnishing a press release on Q3 2026 earnings for the quarter ended September 30, 2026, and a corporate presentation, both attached as exhibits and both described as furnished rather than filed.